NasdaqGS:BMRNBiotechs
BioMarin Pharmaceutical (BMRN) Could Be 30% Below Fair Value On Raised Guidance
BioMarin Pharmaceutical (BMRN) has just released its second quarter 2026 results, giving investors fresh detail on how revenue, earnings and guidance are evolving after its rare disease expansion.
See our latest analysis for BioMarin Pharmaceutical.
BioMarin Pharmaceutical’s Q2 earnings release and raised guidance have come alongside a 13.69% 90 day share price return and a modest 3.38% year to date share price return, while the 3 year total shareholder return has declined 32.39%, showing...